PLSE Q1 2026 Earnings Report Summary
Pulse Biosciences reported first-quarter earnings for fiscal year 2026 with total revenue of $401,000 and a GAAP net loss of $18.6 million compared to the prior year period. The company highlighted key clinical results from its nPulse Cardiac Catheter System feasibility study.
Tickers: $PLSE
Topics: cash_balance clinical_trials expenses net_loss revenue